Tizanidine Tablets Recalled for Failed Specifications Due to Shaved Tablets
Dr. Reddy's Laboratories is recalling Tizanidine HCl 4 mg tablets nationwide because some tablets are shaved, failing the required tablet specification.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for a failed tablet specification (shaved tablets). The source text does not report any illnesses, injuries, or hospitalizations. The defect appears to be a manufacturing/quality control issue rather than a safety hazard with confirmed harm, placing it in the Moderate category per the rubric.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Tizanidine HCl Tablets, USP 4 mg (150-count bottles, NDC 55111-180-15) due to a failed tablet specification. Some tablets in the affected lots are shaved, which means they do not meet the required tablet specifications for quality and safety.
The recalled product was distributed nationwide within the United States. The affected lot is T2000471 with an expiration date of 09/2023, totaling 37,560 bottles.
Tizanidine is a prescription medication used to treat muscle spasms. Consumers who have this medication should check their bottles for lot number T2000471. If you have this product, contact your pharmacist or healthcare provider for guidance on whether your specific bottle is affected and what steps to take next. Do not use the medication if you suspect it may be from the recalled lot.
The recalled product
- Product
- TIZANIDINE (TIZANIDINE)
- Brand
- TIZANIDINE
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Hazard
- failed-tablet-specification
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: T2000471
- exp date 09/2023
UPCs (2)
- 0355111180104
- 0355111179108
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TIZANIDINE
- HighTizanidine 4mg Tablets Recalled for Contamination with 2mg Tablets
FDA (Drugs) · 2024-01-17
- HighTizanidine Tablets Recalled Nationwide for Failed Dissolution Specification
FDA (Drugs) · 2023-07-26
- ModerateTizanidine tablets recalled nationwide for failed stability specifications
FDA (Drugs) · 2023-07-12
- ModeratePrescription Drug Tizanidine Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2023-07-12
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27